ANDA 207515, held by Amneal Pharmaceuticals. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 207515 (Methylphenidate Hydrochloride), held by Amneal Pharmaceuticals, was first approved by FDA on Feb 1, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2018 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride27MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride36MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride54MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| May 15, 2024 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| May 15, 2024 | Supplement 17Labeling ยท Standard review | Approved | None posted |
| Feb 1, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters